New imaging agent for head and neck cancer surgery
Part of Cancer clinical trials.
This study tests a new imaging agent that may help doctors see cancer more clearly during surgery to remove head and neck tumors. The goal is to improve surgical accuracy and potentially reduce the chance of leaving cancer behind.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with head and neck cancer (squamous cell carcinoma) that can be removed with surgery.
- Your cancer is in the mouth, throat, voice box, or the area behind the nose and mouth.
- You do not have severe liver or kidney problems.
- You are not pregnant or breastfeeding, and you are not currently taking anti-EGFR targeted therapy (like cetuximab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This study tests a new imaging agent (a special dye) that might help doctors see tumors more clearly in people with certain advanced cancers. You would receive the dye and then have scans to see if it highlights cancer areas.
This trial compares giving immunotherapy alone versus immunotherapy plus focused radiation before surgery for head and neck cancer. The goal is to see if adding radiation helps shrink the tumor and improve outcomes.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.